Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 15/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | PRNP | P04156 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | NR2E3 | Q9Y5X4 | 1/20 | 0.38 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2213799 | 0.98 | OPRK1 (0.56) | OPRK1ALDH1A1HTTMAPK1LMNA | |
| SCHEMBL27159916 | 0.86 | OPRK1 (0.48) | OPRK1ALDH1A1MAPK1LMNAMAPT | |
| SCHEMBL21170840 | 0.82 | OPRK1 (0.69) | OPRK1ALDH1A1HTTMAPK1LMNA | |
| SCHEMBL16944616 | 0.81 | OPRK1 (0.78) | OPRK1 | |
| SCHEMBL13010703 | 0.80 | HTT (0.50) | OPRK1SMN1; SMN2HTTMAPK1LMNA | |
| SCHEMBL6103809 | 0.80 | OPRK1 (0.51) | OPRK1 | |
| SCHEMBL6104537 | 0.78 | OPRK1 (0.58) | OPRK1 | |
| SCHEMBL2213986 | 0.77 | OPRK1 (0.49) | OPRK1ALDH1A1SMN1; SMN2HTTMAPT | |
| SCHEMBL18994652 | 0.77 | OPRK1 (0.57) | OPRK1 | |
| SCHEMBL14470632 | 0.76 | SCN10A (0.48) | ALDH1A1SMN1; SMN2LMNAMAPTNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060160864-A1 | Acrylamide derivative, process for producing the same, and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-07-20 | — | — | US | disclosed |
| EP-1593673-A1 | ACRYLAMIDE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE | Takeda Pharmaceutical Company Limited (JP) | 2005-11-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160864-A1 | Acrylamide derivative, process for producing the same, and use | CCR5, MSR1, CCR2 | OPRK1 980/4885ALDH1A1 1414/4885SMN1; SMN2 2871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.